Trials / Unknown
UnknownNCT05425472
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
An Open, Single-arm, Multicenter Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR070803 | HR070803 |
Timeline
- Start date
- 2022-07-27
- Primary completion
- 2023-01-30
- Completion
- 2023-03-30
- First posted
- 2022-06-21
- Last updated
- 2022-09-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05425472. Inclusion in this directory is not an endorsement.